The HLA-A*02, B*62 supertype may act as a favourable prognostic factor for immunotherapy in patients with NSCLC, as it is associated with a PD-L1-positive tumour microenvironment [43]. The gene discussed is HLA-A; the disease is non-small cell lung carcinoma.